The ongoing public
health emergency of opioid use disorders (OUD)
and overdose in the United States is largely driven by fentanyl and
its related analogues and has resulted in over 75 673 deaths
in 2021. Immunotherapeutics such as vaccines have been investigated
as a potential interventional strategy complementary to current pharmacotherapies
to reduce the incidence of OUD and opioid-related overdose. Given
the importance of targeting structurally distinct fentanyl analogues,
this study compared a previously established lead conjugate vaccine
(F
1
–CRM) to a series of novel vaccines incorporating
haptens derived from alfentanil and acetylfentanyl (F
8, 9a, 9b, 10
), and evaluated their efficacy against drug-induced pharmacological
effects in rats. While no vaccine tested provided significant protection
against alfentanil, lead formulations were effective in reducing antinociception,
respiratory depression, and bradycardia elicited by fentanyl, sufentanil,
and acetylfentanyl. Compared with control, vaccination with F
1
–CRM also reduced drug levels in the brain of rats
challenged with lethal doses of fentanyl. These data further support
investigation of F
1
–CRM as a candidate vaccine against
fentanyl and selected analogues.